AbbVie: 3 Key Takeaways for Long-Term Investors

AbbVie, the pharmaceutical company, reported its third quarter earnings on Oct. 30, 2026. The company raised its full-year revenue guidance to $67.8 billion, reflecting increased sales in its immunology and neuroscience businesses. AbbVie's focus on newer treatments, such as Skyrizi for inflammatory bowel disease (IBD) and an FDA-approved subcutaneous induction option for Crohn's disease, is crucial for sustaining double-digit growth beyond the patent expiry of its blockbuster medication, Humira, according to key takeaways for long-term investors.

Jeffrey Stewart, AbbVie's Executive Vice President and Chief Commercial Officer, highlighted the company's strong performance in IBD, with Skyrizi capturing half of all new patients starting therapy. The subcutaneous induction dosing for Crohn's disease is expected to further bolster AbbVie's competitive position in IBD. Robert Michael, AbbVie's Chairman and Chief Executive Officer, announced the FDA approval of Juvmo for Parkinson's disease, which, along with Vyalev and Duopa, could generate peak sales exceeding $5 billion.

This expansion in the neuroscience division, coupled with strong cash flow generation of $14 billion in the first nine months of the year and a 5.2% dividend increase to $1.82 per share, positions AbbVie for top-tier growth and a projected net leverage ratio of two times within two to three years.